Podcast: Psychedelics in D.C., FDA’s Framework, and New Zealand’s MDMA Prescribers

Josh Hardman’s first episode of The Psychedelic News Feed reviews major psychedelic drug development, policy, and access developments from a busy two-week period. The discussion covers three events in Washington, D.C., including an FDA public hearing, an ARPA-H workshop related to ibogaine, and a congressional briefing. It also examines a commentary from senior FDA staff proposing a framework for psychedelic drug development and New Zealand’s approval of two psychiatrists to prescribe MDMA for PTSD. Additional headlines include Definium Therapeutics’ positive Phase 3 LSD results for generalized anxiety disorder, new Compass Pathways data on psilocybin for treatment-resistant depression, the entry of Xylo’s neuroplastogen into clinical testing, Eli Lilly’s acquisition of AtaiBeckley, RFK Jr.’s discussion of ibogaine with Bryan Hubbard, and Usona Institute’s trademark filing for “Arumaya,” a potential psilocybin brand name. The podcast is published every two weeks.